• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Abbott, Camdiab, Ypsomed forge partnership for automated insulin delivery

April 27, 2022 By Sean Whooley

Abbott FreeStyle Libre 3 CamDiab Ypsomed ypsopump
[Image from Abbott, CamDiab and Ypsomed]
Abbott (NYSE:ABT) announced today that it partnered with CamDiab and Ypsomed (SWX:YPSN) to produce an integrated automated insulin delivery (AID) system.

The companies announced the partnership at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona, Spain. It seeks to develop and commercialize the integrated AID system with an initial focus centered around European countries.

According to a news release, the partnership aims to design the integrated AID system to connect Abbott’s FreeStyle Libre 3 sensor — touted as the world’s smallest and most accurate continuous glucose monitoring sensor (CGM) with readings every minute — to CamDiab’s CamAPS FX mobile app, which connects with Ypsomed’s mylife YpsoPump.

The companies said that the combination of all devices and platforms in the partnership creates a smart, automated process for insulin delivery based on real-time glucose data. The wearable system will continuously monitor glucose levels and automatically adjust and deliver the proper amount of insulin at the right time.

Development is expected to finish by the end of 2022, with commercial availability anticipated thereafter.

“Our goal is to make diabetes care as easy as possible, which is why Abbott continues to expand its team of insulin delivery partners, digital coaching and technology leaders,” SVP of Abbott’s Diabetes Care Business Jared Watkin said in the release. “We want to deliver new advanced solutions that simplify and make it possible for people to spend less time thinking about diabetes and more time living.”

Last month, Ypsomed and CamDiab announced a collaboration on managing automated insulin delivery with a mobile app, with plans to launch CamDiab’s CamAPS FX app for managing glucose levels via insulin pumps using an adaptive, hybrid closed-loop approach, for automated insulin delivery (AID) with Ypsomed’s MyLife YpsoPump system during the first half of 2022.

“We want to help people with diabetes better manage their glucose through advanced technology,” CamDiab Director Roman Hovorka said. “Our CamAPS FX, already approved in Europe, is a highly adaptive algorithm that when integrated with Abbott’s sensor is being designed to communicate with Ypsomed’s insulin pump to provide the optimal insulin dose, lifting the burden of managing a condition that is relentlessly unpredictable day and night.”

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: abbott, CamDiab, Ypsomed

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS